ES2196016T3 - Proteina p140 y dna que codifica para la indicada proteina. - Google Patents

Proteina p140 y dna que codifica para la indicada proteina.

Info

Publication number
ES2196016T3
ES2196016T3 ES94118524T ES94118524T ES2196016T3 ES 2196016 T3 ES2196016 T3 ES 2196016T3 ES 94118524 T ES94118524 T ES 94118524T ES 94118524 T ES94118524 T ES 94118524T ES 2196016 T3 ES2196016 T3 ES 2196016T3
Authority
ES
Spain
Prior art keywords
protein
prevention
treatment
phosphorilation
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94118524T
Other languages
English (en)
Inventor
Hisao Tajima
Koichiro Kitagawa
Hiroyuki Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2196016T3 publication Critical patent/ES2196016T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA RELACIONADA CON UN NUEVO POLIPEPTIDO DE LA PROTEINA P140 QUE ES UNA PROTEINA CLAVE IMPLICADA EN EL SISTEMA DE TRANSMISION DE SEÑAL DE LA INSULINA; EL METODO PARA LA PREPARACION DE ELLA; EL DNA QUE CODIFICA DICHO POLIPEPTIDO; EL VECTOR DERIVADO DE DICHO DNA; LAS CELULAS HUESPED TRANSFORMADAS AL DICHO VECTOR; EL ANTICUERPO DEL DICHO POLIPEPTIDO; LA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO PEPTIDO O ANTICUERPO; EL METODO PARA LA PREVENCION Y/O TRATAMIENTO DE LA DIABETES, QUE ESTA CARACTERIZADO POR LA FOSFORILACION DE TIROSINA DE DICHA PROTEINA P140; EL AGENTE PARA LA PREVENCION Y/O TRATAMIENTO PARA LA ACTUALIZACION DE DICHO METODO DE TRATAMIENTO Y/O PREVENCION; EL AGENTE PARA LA PREVENCION Y/O TRATAMIENTO DE LA DIABETES, QUE ESTA CARACTERIZADA POR CONTENER UN COMPONENTE QUE PUEDA LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140, COMO INGREDIENTE ACTIVO Y LOS METODOS DE PROTECCION DE DICHO AGENTE DE TRATAMIENTO Y/O PREVENCION. LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140 ES UN PASO ESENCIAL EN LA INDUCCION DE LA HIPOGLUCEMIA POR LA CAPTACION DE GLUCOSA. EL METODO Y EL AGENTE DE PREVENCION Y/O TRATAMIENTO BASADO EN LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140 EN LA PRESENTE INVENCION NO SOLAMENTE MEJORA LAS CONDICIONES HIPERGLICEMICAS DERIVADAS DE LA DIABETES SINO SON TAMBIEN UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE LA DIABETES, ESPECIALMENTE MELLITUS DE DIABETES NO DEPENDIENTE DE INSULINA.
ES94118524T 1993-11-24 1994-11-24 Proteina p140 y dna que codifica para la indicada proteina. Expired - Lifetime ES2196016T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31580693 1993-11-24

Publications (1)

Publication Number Publication Date
ES2196016T3 true ES2196016T3 (es) 2003-12-16

Family

ID=18069786

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94118524T Expired - Lifetime ES2196016T3 (es) 1993-11-24 1994-11-24 Proteina p140 y dna que codifica para la indicada proteina.

Country Status (11)

Country Link
US (5) US5506205A (es)
EP (1) EP0659883B1 (es)
KR (1) KR100256664B1 (es)
CN (1) CN1057096C (es)
AT (1) ATE237683T1 (es)
CA (1) CA2136565C (es)
DE (1) DE69432511T2 (es)
DK (1) DK0659883T3 (es)
ES (1) ES2196016T3 (es)
PT (1) PT659883E (es)
TW (1) TW311913B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506205A (en) * 1993-11-24 1996-04-09 Ono Pharmaceutical Co., Ltd. Polypeptide of protein p140 and DNAs encoding it
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB0208089D0 (en) 2002-04-09 2002-05-22 Oxford Glycosciences Uk Ltd Protein
EP2046313A4 (en) * 2006-07-10 2012-01-25 Glucox Biotech Ab USE OF NAPHTHOCHINONES IN THE TREATMENT AND CONTROL OF DIABETES, INSULIN RESISTANCE AND HYPERGLYCEMIA
US8440208B2 (en) * 2007-05-01 2013-05-14 Board Of Regents, The University Of Texas System Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
JP4798125B2 (ja) * 2007-12-13 2011-10-19 株式会社デンソー 照度センサ
CN105085630A (zh) * 2015-08-31 2015-11-25 苏州普罗达生物科技有限公司 mTOR抑制多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260200A (en) * 1991-01-18 1993-11-09 Joslin Diabetes Center, Inc. Isolated DNA encoding an insulin receptor substrate
US5817471A (en) * 1991-03-14 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5506205A (en) * 1993-11-24 1996-04-09 Ono Pharmaceutical Co., Ltd. Polypeptide of protein p140 and DNAs encoding it

Also Published As

Publication number Publication date
US5506205A (en) 1996-04-09
KR100256664B1 (ko) 2000-05-15
US6432913B1 (en) 2002-08-13
US20030170865A1 (en) 2003-09-11
TW311913B (es) 1997-08-01
CN1112127A (zh) 1995-11-22
US6303320B1 (en) 2001-10-16
EP0659883A2 (en) 1995-06-28
KR950014135A (ko) 1995-06-15
CA2136565A1 (en) 1995-05-25
DK0659883T3 (da) 2003-08-04
CA2136565C (en) 1999-11-09
EP0659883B1 (en) 2003-04-16
US5804411A (en) 1998-09-08
DE69432511T2 (de) 2004-04-29
DE69432511D1 (de) 2003-05-22
EP0659883A3 (en) 1997-06-25
CN1057096C (zh) 2000-10-04
PT659883E (pt) 2003-07-31
ATE237683T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
Turner et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee
Steinritz et al. Medical documentation, bioanalytical evidence of an accidental human exposure to sulfur mustard and general therapy recommendations
Leong et al. Cross neutralization of Afro-Asian cobra and Asian krait venoms by a Thai polyvalent snake antivenom (Neuro Polyvalent Snake Antivenom)
Loughnan et al. Chemical and functional identification and characterization of novel sulfated α-conotoxins from the cone snail conus a nemone
Sarac et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo
PE20040560A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2196016T3 (es) Proteina p140 y dna que codifica para la indicada proteina.
Leong et al. Immunological cross-reactivity and neutralization of the principal toxins of Naja sumatrana and related cobra venoms by a Thai polyvalent antivenom (Neuro Polyvalent Snake Antivenom)
CN101172100A (zh) 稳定等渗的冻干蛋白质制剂
Sevigny et al. Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
Nahai et al. IncobotulinumtoxinA (Xeomin) Background, Mechanism of Action, and Manufacturing
Mancuso et al. Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study
Woodley et al. Recessive dystrophic epidermolysis bullosa: advances in the laboratory leading to new therapies
Chen et al. A neuropeptide Y/F-like polypeptide derived from the transcriptome of Turbinaria peltata suppresses LPS-induced astrocytic inflammation
Andreosso et al. Dose and time dependence of box jellyfish antivenom
Holfeld et al. Immunogenicity and pharmacokinetics of short, proline-rich antimicrobial peptides
Roine et al. Randomized trial of fourvs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery
Hawking et al. The trypanocidal action of human serum and of baboon plasma
Eng et al. Formulation development and primary degradation pathways for recombinant human nerve growth factor
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.
Iozzo et al. Senile lower lid entropion successfully treated with botulinum toxin A
Penggabean et al. Efficacy of albendazole in the treatment of Trichuris trichuria and Giardia intestinalis infection in rural Malay communities.
Hekman et al. Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product
Gómez et al. Intraspecific variability of the Central American rattlesnake (Crotalus simus) venom and its usefulness to obtain a representative standard venom